Company intelligence / Profile preview

ELIAS Animal Health

Olathe, Kansas, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

ECI® became the first USDA-approved adoptive cell therapy for canine osteosarcoma in 2025, demonstrating improved quality of life and potential survival benefits over standard chemotherapy. More than 300 canine patients have been treated in studies and early access programs. The platform is expanding to other cancer types and includes an oncolytic virotherapy (ELI352) in preclinical research.

Therapeutic areas: Oncology
Modalities: VaccineCell therapyOncolytic virus therapy
Industry: Veterinary

Beyond the preview

Go deeper on ELIAS Animal Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELIAS Animal Health.

Explore the full profile